LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stock Has Consensus Price Target of $105.60 According to Analysts

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has been assigned a consensus rating of “Hold” from the eight analysts that are currently covering the stock, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $108.25.

Several research analysts recently issued reports on the stock. Weiss Ratings lowered shares of LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, October 23rd. Citizens Jmp began coverage on LeMaitre Vascular in a research report on Thursday, November 5th. They issued a “market outperform” rating and a $110.00 price target for the company. Seaport Research Partners set a $110.00 target price on shares of LeMaitre Vascular in a research report on Thursday, November 5th. Wall Street Zen lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, Wells Fargo & Company reduced their price objective on LeMaitre Vascular from $94.00 to $86.00 and set an “equal weight” rating for the company in a report on Thursday, November 5th.

Institutional Trading of LeMaitre Vascular

A number of hedge funds and other institutional investors have recently bought and sold shares of LMAT. BlackRock Inc. bought a new position in shares of LeMaitre Vascular during the 2nd quarter valued at about $314,075,000. First Trust Advisors LP boosted its stake in shares of LeMaitre Vascular by 3.9% during the 3rd quarter. First Trust Advisors LP now owns 1,135,637 shares of the medical instruments supplier’s stock valued at $93,792,000 after purchasing an additional 42,135 shares in the last quarter. Copeland Capital Management LLC boosted its position in LeMaitre Vascular by 10.1% during the 3rd quarter. Copeland Capital Management LLC now owns 924,081 shares of the medical instruments supplier’s stock valued at $76,320,000 after acquiring an additional 84,618 shares in the last quarter. Advisors Asset Management Inc. purchased a new stake in LeMaitre Vascular in the third quarter worth $49,581,000. Finally, Boston Trust Walden Corp bought a new position in shares of LeMaitre Vascular in the 3rd quarter worth about $28,546,000. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Price Performance

Shares of LMAT opened at $78.29 on Monday. The stock has a market cap of $1.79 billion, a PE ratio of 28.24, a PEG ratio of 2.29 and a beta of 0.51. The business has a 50-day simple moving average of $81.31 and a two-hundred day simple moving average of $93.95. The company has a quick ratio of 12.54, a current ratio of 14.60 and a debt-to-equity ratio of 0.39. LeMaitre Vascular has a 12-month low of $77.46 and a 12-month high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Wednesday, November 4th. The medical instruments supplier reported $0.65 earnings per share for the quarter, missing analysts’ consensus estimates of $0.69 by ($0.04). LeMaitre Vascular had a net margin of 23.51% and a return on equity of 15.33%. The firm had revenue of $67.97 million for the quarter, compared to analyst estimates of $67.39 million. During the same period in the prior year, the company posted $0.75 EPS. The business’s revenue for the quarter was up 11.3% compared to the same quarter last year. Analysts anticipate that LeMaitre Vascular will post 2.83 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Thursday, November 19th will be given a dividend of $0.25 per share. The ex-dividend date is Thursday, November 19th. This represents a $1.00 annualized dividend and a dividend yield of 1.3%. LeMaitre Vascular’s dividend payout ratio is currently 36.36%.

About LeMaitre Vascular

LeMaitre Vascular develops, manufactures and markets medical devices used primarily in the treatment of vascular disease. Its products support procedures performed by vascular surgeons and include vascular grafts, embolectomy catheters, carotid shunts, valvulotomes and other instruments used in vascular surgery. Founded in 1983 by vascular surgeon George LeMaitre, the company is headquartered in Burlington, Massachusetts. Its products are sold to hospitals and medical professionals around the world through a combination of direct sales and distributors.